Skip to main content
BICYCLE THERAPEUTICS PLC logo

BICYCLE THERAPEUTICS PLC — Investor Relations & Filings

Ticker · BCYC ISIN · US0887861088 LEI · 213800XKUI6R7GKC3E43 US Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2019-09-30 Board/Management Inform…
Country GB United Kingdom
Listing US BCYC

About BICYCLE THERAPEUTICS PLC

https://www.bicycletherapeutics.com/

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines known as Bicycle® molecules. These are fully synthetic bicyclic peptides engineered to combine the targeting specificity and pharmacological properties of large molecule biologics with the rapid and deep tissue penetration of small molecules. The company's proprietary platform creates precision-guided therapeutics to address diseases underserved by existing treatments. The primary focus of its development pipeline is in oncology, with a portfolio of candidates designed to target solid tumors. Beyond oncology, Bicycle Therapeutics leverages its technology through collaborations to explore applications in other therapeutic areas, including anti-infectives, cardiovascular diseases, and central nervous system disorders.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 26, 2019, for Bicycle Therapeutics plc. The content focuses on Item 5.02, which relates to the departure, election, or appointment of directors or certain officers, including amended and restated employment agreements for executives and changes to the non-employee director compensation policy. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The document is not a proxy statement, call transcript, or other report types. The primary subject is management changes and compensation arrangements for executives and directors, which fits the category of Board/Management Information (MANG). The document length (11,611 characters) and detailed content support this classification with high confidence.
2019-09-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 28, 2019. It reports an event under Item 8.01 "Other Events," specifically announcing a press release about a presentation at the ESMO 2019 Annual Congress regarding updated clinical trial data. The document is relatively short (3729 characters) and primarily serves as a current report to disclose this event and the press release. There are no financial statements or detailed financial data included. The nature of the filing is a regulatory announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories.
2019-09-30 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2019, by Bicycle Therapeutics plc. It announces the issuance of a press release containing financial results for the fiscal quarter ended June 30, 2019. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The text explicitly states that the information is being furnished as an exhibit and is not deemed filed for certain regulatory purposes. This indicates the document is an announcement of financial results rather than the full earnings release or quarterly report itself. Given the nature of the filing (Form 8-K) and the content (announcement of financial results via press release), the most appropriate classification is Earnings Release (ER). The document is short (4141 characters) and primarily serves to announce the earnings release rather than provide full financial details, which aligns with the ER category rather than a full Interim/Quarterly Report (IR).
2019-08-08 English
FORM 3 SUBMISSION
Director's Dealing
2019-07-26 English
FORM 3 SUBMISSION
Director's Dealing
2019-07-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.